Results 201 to 210 of about 2,223,665 (257)

Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: molecular basis and new targets. [PDF]

Front Oncol
Peng H, Li M, Peng YY, Li XL, Yang J, Sun QG, Song K.   +6 more
europepmc   +1 more source

Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response

Cancer Science, Volume 117, Issue 9, Page 2567-2585, September 2026.
Hypericin induces autophagic AKT degradation by promoting AKT‐HSPA5 interaction in an S473 phosphorylation‐dependent manner, suppressing HCC growth. It enhances CD8+ T cell‐mediated antitumor immunity and synergizes with anti‐PD‐L1 therapy, showing favorable safety for HCC treatment. ABSTRACT Hepatocellular carcinoma (HCC) is the most prevalent primary
Sien Ma, Qianqian Xu, Mengjuan Zhu, Xianming Ge, Jian Xu, Yan Pan, Mengli Wang, Yuting Zhu, Aoxuan Xu, Hanmeng Liu, GuangHai Xiang, Weipeng Gong, Bao Zhao   +12 more
wiley   +1 more source

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma. [PDF]

Sci Rep
Qiu Q, Yin H, Zhang L, Xu W, Zhu S, Zhang Q, Zhao M, Qian Y, Ruan Y, Zhang H, Wu Z, Liu J, Ke J, Dai Y, Wang W, Sun W, Gao Y, Xu H.   +17 more
europepmc   +1 more source

FLT3‐ITD Measurable Residual Disease in Acute Myeloid Leukemia: Recommended, but Not Yet Self‐Sufficient

Hematological Oncology, Volume 44, Issue 5, September 2026.
Francesco Albano
wiley   +1 more source

Targeting m6A Modifications Regulating Ferroptosis Offers Novel Therapy in Diseases

Cell Proliferation, Volume 59, Issue 9, September 2026.
m6A RNA modification regulates ferroptosis by balancing iron metabolism, lipid peroxidation, and antioxidant defenses. Dysregulated m6A signaling disrupts pro‐ and anti‐ferroptotic factors, leading to excess ROS, Fe3+ accumulation, and lipid peroxidation–driven cell death. Targeting m6A‐mediated ferroptotic regulation represents a promising therapeutic
Lida Du, Joshua S. Fleishman, Shuang Wu, Yuan Zhou, Clara X. Wang, Haitong Wang, Yumin Wang, Hongquan Wang   +7 more
wiley   +1 more source

Identifying genes associated with Sorafenib resistance in hepatocellular carcinoma to develop risk model. [PDF]

Discov Oncol
He K, Hui H, Zhou F, Liu K, Zhao X, Liu J.   +5 more
europepmc   +1 more source

Autophagy in MASLD: A Metabolic and Precision Medicine Perspective

Liver International, Volume 46, Issue 9, September 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide and a major contributor to cirrhosis and hepatocellular carcinoma (HCC). While metabolic triggers such as obesity and insulin resistance are key drivers of MASLD, growing evidence has identified defects in intracellular quality
Alessandra Cazzaniga, Silvia Frigo, Alessandro Cherubini, Eniada Rrapaj, Luca Valenti   +4 more
wiley   +1 more source

Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4/CYP26A1-retinoic acid axis to drive ferroptosis. [PDF]

J Exp Clin Cancer Res
Yang T, Han Y, Wang Y, Li R, Zhang X, Zhang X, Xu X, Xu J, Li X, Lin C, Wang W, Yang J.   +11 more
europepmc   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

FBXO2 promotes hepatocellular carcinoma progression and sorafenib resistance by targeting USP49 for proteasomal degradation. [PDF]

Front Immunol
Hang S, Wang Q, Zhang J, Dong Y, Hu B, Wang P, Xu L.   +6 more
europepmc   +1 more source